{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-019359","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.298638+00:00","generated_at":"2026-05-27T04:07:28.899154+00:00","sec_items":["1.01","1.02","2.03","3.01","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Omega Therapeutics enters RSA for Chapter 11, plans asset sale after loan default","bullets":["Entered Restructuring Support Agreement with Flagship affiliate for $1.4M bridge loan and DIP loan to fund Chapter 11 process.","Plans to file Chapter 11 by Feb 10, 2025; seeks Bankruptcy Court approval for stalking horse asset sale to Supporting Party.","Received Nasdaq delisting notice for bid price below $1; has until July 28, 2025 to regain compliance.","Loan from Banc of California terminated after default notice and setoff of $14.7M; company believes default not valid.","Approved workforce reduction of up to 17 employees and retention bonuses for CEO ($40K) and CAO ($81.4K)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-019359","json":"https://secwatch.observer/filing/0001193125-25-019359.json","markdown":"https://secwatch.observer/filing/0001193125-25-019359.md","text":"https://secwatch.observer/filing/0001193125-25-019359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/d927659d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:07:28.899154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad378de7f5d1c163ab582bba9bb8e2e768283c94","claim":"Omega Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.02, 3.01, 5.02, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001437749-26-016538","ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T12:03:45+00:00","headline":"Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB","event_type":"other_material","sec_items":["3.01","8.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016538","json":"https://secwatch.observer/filing/0001437749-26-016538.json","markdown":"https://secwatch.observer/filing/0001437749-26-016538.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm"}},{"accession":"0001493152-26-024495","ticker":"SOPA","company_name":"SOCIETY PASS INCORPORATED.","filed_at":"2026-05-20T10:05:33+00:00","headline":"Society Pass receives Nasdaq delisting notice after filing Chapter 11 bankruptcy","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024495","json":"https://secwatch.observer/filing/0001493152-26-024495.json","markdown":"https://secwatch.observer/filing/0001493152-26-024495.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"May 14, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nthat Nasdaq had determined to delist the Company’s common stock, par value $0.0001 per share (the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm"}},{"accession":"0001193125-26-230708","ticker":"BTM","company_name":"Bitcoin Depot Inc.","filed_at":"2026-05-19T20:01:24+00:00","headline":"Bitcoin Depot files Chapter 11; Nasdaq to suspend BTM stock and warrants on May 26","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-230708","json":"https://secwatch.observer/filing/0001193125-26-230708.json","markdown":"https://secwatch.observer/filing/0001193125-26-230708.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/d228011d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"May 18, 2026, the Company received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Debtors’ commencement of the Chapter 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm"}},{"accession":"0001437749-26-016455","ticker":"BKYI","company_name":"BIO KEY INTERNATIONAL INC","filed_at":"2026-05-12T20:46:03+00:00","headline":"BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016455","json":"https://secwatch.observer/filing/0001437749-26-016455.json","markdown":"https://secwatch.observer/filing/0001437749-26-016455.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/bkyi20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm"}},{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001880613-26-000050","ticker":"DRCT","company_name":"Direct Digital Holdings, Inc.","filed_at":"2026-04-28T23:59:59+00:00","headline":"DRCT enters $50M equity line with Roth, terminates New Circle ELOC, receives Nasdaq delisting notice","event_type":"other_material","sec_items":["1.01","1.02","3.01","3.03","5.03","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 1.02, 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001880613-26-000050","json":"https://secwatch.observer/filing/0001880613-26-000050.json","markdown":"https://secwatch.observer/filing/0001880613-26-000050.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880613/000188061326000050/0001880613-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880613/000188061326000050/drct-20260423.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"April 23, 2026, the Company received an Additional Staff Delisting Determination Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in comp","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1880613/000188061326000050/0001880613-26-000050-index.htm"}},{"accession":"0001829126-26-004960","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-11T21:08:14+00:00","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","event_type":"other_material","sec_items":["1.01","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004960","json":"https://secwatch.observer/filing/0001829126-26-004960.json","markdown":"https://secwatch.observer/filing/0001829126-26-004960.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm","comparable_excerpt":"May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}